NCT01143025

Brief Summary

The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 50 mg, 100 mg or 150 mg may prevent the use of morphine during the first day after laparoscopic cholecystectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
165

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2010

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 9, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 14, 2010

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2011

Completed
Last Updated

May 19, 2011

Status Verified

May 1, 2010

Enrollment Period

1.1 years

First QC Date

June 9, 2010

Last Update Submit

May 18, 2011

Conditions

Keywords

Laparoscopic CholecystectomyNebulizationRopivacaine

Outcome Measures

Primary Outcomes (1)

  • Morphine consumption (mg)

    The total dose of morphine at every evaluation after awakening will be quantified using the PACU clinical chart and/or PCA infusers memory display

    Up to 48 hours

Secondary Outcomes (7)

  • Ropivacaine pharmacokinetics profile: Plasma Concentration of Ropivacaine

    Up to 360 minutes

  • Ropivacaine pharmacokinetics profile: Tissue drug analysis

    Up to 2 hours

  • Postoperative Pain

    Up to 48 hours

  • Time of unassisted walking

    Up to 48 hours

  • Hospital morbidity

    Up to 48 hours

  • +2 more secondary outcomes

Study Arms (3)

Ropivacaine 50 mg

ACTIVE COMPARATOR

Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity

Drug: Ropivacaine 50 mg

Ropivacaine 100 mg

EXPERIMENTAL

Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity

Drug: Ropivacaine 100 mg

Ropivacaine 150 mg

EXPERIMENTAL

Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity

Drug: Ropivacaine 150 mg

Interventions

Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity

Also known as: Nebulization, Ropivacaine
Ropivacaine 50 mg

Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity

Also known as: Nebulization, Ropivacaine
Ropivacaine 100 mg

Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity

Also known as: Nebulization, Ropivacaine
Ropivacaine 150 mg

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Females and Males 18-75 years old
  • ASA Score I-III
  • Scheduled for laparoscopic cholecystectomy
  • Free from pain in preoperative period
  • Not using analgesic drugs before surgery
  • Without cognitive impairment or mental retardation
  • Written informed consent

You may not qualify if:

  • Emergency/urgency surgery
  • Postoperative admission in an intensive care unit
  • Cognitive impairment or mental retardation
  • Progressive degenerative diseases of the CNS
  • Seizures or chronic therapy with antiepileptic drugs
  • Severe hepatic or renal impairment
  • Pregnancy or lactation
  • Allergy to one of the specific drugs under study
  • Acute infection or inflammatory chronic disease
  • Alcohol or drug addiction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Gerardo Hospital

Monza, MB, 20052, Italy

Location

Related Publications (3)

  • Greib N, Schlotterbeck H, Dow WA, Joshi GP, Geny B, Diemunsch PA. An evaluation of gas humidifying devices as a means of intraperitoneal local anesthetic administration for laparoscopic surgery. Anesth Analg. 2008 Aug;107(2):549-51. doi: 10.1213/ane.0b013e318176fa1c.

    PMID: 18633034BACKGROUND
  • Schlotterbeck H, Schaeffer R, Dow WA, Diemunsch P. Cold nebulization used to prevent heat loss during laparoscopic surgery: an experimental study in pigs. Surg Endosc. 2008 Dec;22(12):2616-20. doi: 10.1007/s00464-008-9841-z. Epub 2008 Mar 18.

    PMID: 18347861BACKGROUND
  • Alkhamesi NA, Peck DH, Lomax D, Darzi AW. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial. Surg Endosc. 2007 Apr;21(4):602-6. doi: 10.1007/s00464-006-9087-6. Epub 2006 Dec 16.

MeSH Terms

Interventions

Ropivacaine

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Massimo Allegri, MD

    Servizio Anestesia e Rianimazione I e Terapia del Dolore, Fondazione IRCCS Policlinico San Matteo, Pavia

    STUDY CHAIR
  • Mario Regazzi, MD

    Head of Clinical PK and TDM Laboratory, Foundation IRCCS Policlinico San Matteo, Pavia

    STUDY CHAIR
  • Ernesto Pizzirani, MD

    U.O.C. Anestesia e Rianimazione. A.O. U.L.S.S.15 "Alta Padovana", Presidio Camposampiero. Camposampiero - Padova

    STUDY CHAIR
  • Fiorenza Franceschi, MD

    U.O.C. Anestesia e Rianimazione. A.O. U.L.S.S.15 "Alta Padovana", Presidio Camposampiero. Camposampiero - Padova

    STUDY CHAIR
  • Armando Alborghetti, MD

    U.O.C. Anestesia e Rianimazione. Ospedale di Ponte San Pietro. Bergamo

    STUDY CHAIR
  • Alessandro Albani, MD

    U.O. Anestesia e Rianimazione. Ospedale Regionale "U. Parini", Aosta

    STUDY CHAIR
  • Pierre Diemusch, MD

    Servizio di Anestesia e rianimazione chirurgica. Hospital de Hautepierre. Università di Strasburgo.

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 9, 2010

First Posted

June 14, 2010

Study Start

March 1, 2010

Primary Completion

April 1, 2011

Study Completion

May 1, 2011

Last Updated

May 19, 2011

Record last verified: 2010-05

Locations